Natco Pharma receives seven FDA Form 483 observations at Chennai API unit

Natco Pharma concluded a US FDA inspection at its Manali, Chennai API facility, resulting in seven Form 483 observations. The company described the findings as procedural, not related to product quality, and said it will submit a comprehensive response. The inspection ran from November 17–21, 2025.

Show more

Stay Ahead – Explore Now! Equity on the Fast Lane: Renault’s Bold Employee Share Plan Accelerates Value Sharing